Text full multimedia monochrome

First time here?

Find out more about how The Lecture List works.

Coronavirus situation update

Our lecture organisers may or may not have had time to update their events with cancellation notices. Clearly social gatherings are to be avoided and that includes lectures. STAY AT HOME FOLKS, PLEASE.

Help!

Find out what you can do to keep The Lecture List online

Why haven't we cured cancer yet?

A look at stimuli-responsive microbubbles and how they are revolutionising cancer treatment.


Despite extraordinary advances in cancer treatment over the past century, the medical profession still quotes patient survival in terms of 3 to 5 years. Complete remission of the disease remains the exception and the impact of new treatments has been highly diverse.

Cancer still affects 1 in 3 of us, so what are we going to do about it?

Oxford University’s Professor Eleanor Stride believes that ‘stimuli-responsive’ particles, delivering medicine directly to the target site could be the answer. In this year’s first Future Science EngTalk, she’ll introduce her work with ‘microbubbles’, the challenges of new drug delivery strategies and their potential for improving treatment of major diseases such as cancer or stroke.

You’ll also hear a 10-minute insight from Dr Jack Kreindler, Founder of The Centre for Health and Human Performance. Is a dollar a day all it takes for us to live to 100?

Tickets to this exciting evening are free, but expected to go fast!


Speaker(s):

Professor Eleanor Stride | talks | www
Dr Jack Kreindler | talks | www

 

Date and Time:

4 May 2017 at 6:00 pm

Duration:

2 hours 30 minutes

 

Venue:

IET London: Savoy Place
2 Savoy Place
London
WC2R 0BL


Show map

Organised by:

The IET
See other talks organised by The IET...

 

Tickets:

Free to attend

Available from:

http://events.theiet.org/kelvin/index.cfm?origin=the-lecture-list

Register to tell a friend about this lecture.

Comments

If you would like to comment about this lecture, please register here.



 

Any ad revenue is entirely reinvested into the Lecture List's operating fund